Skip to main content

Table 2 EGFR and K-Ras mutational status

From: EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition

  Descriptive cohort (n = 103) Correlative cohort (n = 66) Anti-EGFR treated (n = 39)
  n % n % n %
EGFR mutational status       
  Wild-type 72 70 47 71 24 62
  Mutant 31 30 19 29 15 38
Sites of EGFR mutation       
  Exon 19 deletion 24 77* 14 74* 12 80*
E746_A750del 19 62* 10 54* 8 52*
E746_R748del 1 3* 1 5* - -
E746_E749 > Y 1 3* 1 5* 1 7*
L747_A750>P 1 3* 1 5* 1 7*
L747_T751del 1 3* 1 5* 1 7*
S751_I759del 1 3* - - 1 7*
  Exon 20 mutation 3 10* 2 10* - -
G796D 2 7* 1 5* - -
A767_V769dup 1 3* 1 5* - -
  Exon 21 mutation 4 13* 3 16* 3 20*
L858R 4 13* 3 16* 3 20*
K-Ras mutational status       
  Wild-type 76 73 46 70 30 77
  Mutant 13 13 9 14 4 10
  Not evaluable 14 14 11 16 5 13
Sites of K-Ras mutation       
  Codon 12 mutation 10 77* 7 78* 4 100*
G12C 6 46* 4 44* 3 75*
G12D 1 8* - - - -
G12V 3 23* 3 34* 1 25*
  Codon 13 mutation 3 23* 2 22* - -
G13D 3 23* 2 22* - -
  1. *Calculated as % of total EGFR and K-Ras mutations in each patient cohort.